Literature DB >> 34910552

Signatures of immune selection in intact and defective proviruses distinguish HIV-1 elite controllers.

Xiaodong Lian1,2, Ce Gao1,2, Xiaoming Sun1, Chenyang Jiang1,2, Kevin B Einkauf1,2, Kyra W Seiger1,2, Joshua M Chevalier1,2, Yuko Yuki3, Maureen Martin3, Rebecca Hoh4, Michael J Peluso4, Mary Carrington1,3, Ezequiel Ruiz-Mateos5, Steven G Deeks4, Eric S Rosenberg6, Bruce D Walker1,7,8, Mathias Lichterfeld1,2, Xu G Yu1,2.   

Abstract

Increasing evidence suggests that durable drug-free control of HIV-1 replication is enabled by effective cellular immune responses that may induce an attenuated viral reservoir configuration with a weaker ability to drive viral rebound. Here, we comprehensively tracked effects of antiviral immune responses on intact and defective proviral sequences from elite controllers (ECs), analyzing both classical escape mutations and HIV-1 chromosomal integration sites as biomarkers of antiviral immune selection pressure. We observed that, within ECs, defective proviruses were commonly located in permissive genic euchromatin positions, which represented an apparent contrast to autologous intact proviruses that were frequently located in heterochromatin regions; this suggests differential immune selection pressure on intact versus defective proviruses in ECs. In comparison to individuals receiving antiretroviral therapy, intact and defective proviruses from ECs showed reduced frequencies of escape mutations in cytotoxic T cell epitopes and antibody contact regions, possibly due to the small and poorly inducible reservoir that may be insufficient to drive effective viral escape in ECs. About 15% of ECs harbored nef deletions in intact proviruses, consistent with increased viral vulnerability to host immunity in the setting of nef dysfunction. Together, these results suggest a distinct signature of immune footprints in proviral sequences from ECs.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 34910552      PMCID: PMC9202005          DOI: 10.1126/scitranslmed.abl4097

Source DB:  PubMed          Journal:  Sci Transl Med        ISSN: 1946-6234            Impact factor:   19.319


  71 in total

Review 1.  Retroviral restriction by APOBEC proteins.

Authors:  Reuben S Harris; Mark T Liddament
Journal:  Nat Rev Immunol       Date:  2004-11       Impact factor: 53.106

2.  The V1V2 domain and an N-linked glycosylation site in the V3 loop of the HIV-1 envelope glycoprotein modulate neutralization sensitivity to the human broadly neutralizing antibody 2G12.

Authors:  Antoine Chaillon; Martine Braibant; Thierry Moreau; Suzie Thenin; Alain Moreau; Brigitte Autran; Francis Barin
Journal:  J Virol       Date:  2011-01-19       Impact factor: 5.103

3.  Long-term nonprogressive disease among untreated HIV-infected individuals: clinical implications of understanding immune control of HIV.

Authors:  Stephen A Migueles; Mark Connors
Journal:  JAMA       Date:  2010-07-14       Impact factor: 56.272

4.  Combined HIV-1 sequence and integration site analysis informs viral dynamics and allows reconstruction of replicating viral ancestors.

Authors:  Sean C Patro; Leah D Brandt; Michael J Bale; Elias K Halvas; Kevin W Joseph; Wei Shao; Xiaolin Wu; Shuang Guo; Ben Murrell; Ann Wiegand; Jonathan Spindler; Castle Raley; Christopher Hautman; Michele Sobolewski; Christine M Fennessey; Wei-Shau Hu; Brian Luke; Jenna M Hasson; Aurelie Niyongabo; Adam A Capoferri; Brandon F Keele; Jeff Milush; Rebecca Hoh; Steven G Deeks; Frank Maldarelli; Stephen H Hughes; John M Coffin; Jason W Rausch; John W Mellors; Mary F Kearney
Journal:  Proc Natl Acad Sci U S A       Date:  2019-11-27       Impact factor: 11.205

5.  Differential decay of intact and defective proviral DNA in HIV-1-infected individuals on suppressive antiretroviral therapy.

Authors:  Michael J Peluso; Peter Bacchetti; Kristen D Ritter; Subul Beg; Jun Lai; Jeffrey N Martin; Peter W Hunt; Timothy J Henrich; Janet D Siliciano; Robert F Siliciano; Gregory M Laird; Steven G Deeks
Journal:  JCI Insight       Date:  2020-02-27

6.  Effect of antiretroviral therapy on HIV reservoirs in elite controllers.

Authors:  Tae-Wook Chun; J Shawn Justement; Danielle Murray; Connie J Kim; Jana Blazkova; Claire W Hallahan; Erika Benko; Cecilia T Costiniuk; Gabor Kandel; Mario Ostrowski; Rupert Kaul; Susan Moir; Joseph P Casazza; Richard A Koup; Colin Kovacs; Anthony S Fauci
Journal:  J Infect Dis       Date:  2013-07-11       Impact factor: 5.226

7.  Antiretroviral Therapy Reduces T-cell Activation and Immune Exhaustion Markers in Human Immunodeficiency Virus Controllers.

Authors:  Jonathan Z Li; Florencia P Segal; Ronald J Bosch; Christina M Lalama; Carla Roberts-Toler; Heloise Delagreverie; Rachel Getz; Pilar Garcia-Broncano; Jennifer Kinslow; Randall Tressler; Cornelius N Van Dam; Michael Keefer; Mary Carrington; Mathias Lichterfeld; Daniel Kuritzkes; Xu G Yu; Alan Landay; Paul E Sax
Journal:  Clin Infect Dis       Date:  2020-04-10       Impact factor: 9.079

8.  Maintenance of viral suppression in HIV-1-infected HLA-B*57+ elite suppressors despite CTL escape mutations.

Authors:  Justin R Bailey; Thomas M Williams; Robert F Siliciano; Joel N Blankson
Journal:  J Exp Med       Date:  2006-05-08       Impact factor: 14.307

9.  Permanent control of HIV-1 pathogenesis in exceptional elite controllers: a model of spontaneous cure.

Authors:  Concepcion Casado; Cristina Galvez; Maria Pernas; Laura Tarancon-Diez; Carmen Rodriguez; Víctor Sanchez-Merino; Mar Vera; Isabel Olivares; Rebeca De Pablo-Bernal; Alberto Merino-Mansilla; Jorge Del Romero; Ramon Lorenzo-Redondo; Ezequiel Ruiz-Mateos; María Salgado; Javier Martinez-Picado; Cecilio Lopez-Galindez
Journal:  Sci Rep       Date:  2020-02-05       Impact factor: 4.379

10.  Impact of pre-adapted HIV transmission.

Authors:  Jonathan M Carlson; Victor Y Du; Nico Pfeifer; Anju Bansal; Vincent Y F Tan; Karen Power; Chanson J Brumme; Anat Kreimer; Charles E DeZiel; Nicolo Fusi; Malinda Schaefer; Mark A Brockman; Jill Gilmour; Matt A Price; William Kilembe; Richard Haubrich; Mina John; Simon Mallal; Roger Shapiro; John Frater; P Richard Harrigan; Thumbi Ndung'u; Susan Allen; David Heckerman; John Sidney; Todd M Allen; Philip J R Goulder; Zabrina L Brumme; Eric Hunter; Paul A Goepfert
Journal:  Nat Med       Date:  2016-05-16       Impact factor: 53.440

View more
  9 in total

Review 1.  Viral and Host Biomarkers of HIV Remission Post Treatment Interruption.

Authors:  Leila B Giron; Mohamed Abdel-Mohsen
Journal:  Curr HIV/AIDS Rep       Date:  2022-04-19       Impact factor: 5.071

Review 2.  An ordeal that does not heal: understanding barriers to a cure for HIV-1 infection.

Authors:  Mathias Lichterfeld; Ce Gao; Xu G Yu
Journal:  Trends Immunol       Date:  2022-08       Impact factor: 19.709

Review 3.  Role of Ca2+ in healthy and pathologic cardiac function: from normal excitation-contraction coupling to mutations that cause inherited arrhythmia.

Authors:  Joshua A Keefe; Oliver M Moore; Kevin S Ho; Xander H T Wehrens
Journal:  Arch Toxicol       Date:  2022-10-10       Impact factor: 6.168

Review 4.  Defective HIV-1 genomes and their potential impact on HIV pathogenesis.

Authors:  Jeffrey Kuniholm; Carolyn Coote; Andrew J Henderson
Journal:  Retrovirology       Date:  2022-06-28       Impact factor: 3.768

5.  The Characteristics of the HIV-1 Env Glycoprotein Are Linked With Viral Pathogenesis.

Authors:  Silvia Pérez-Yanes; María Pernas; Silvia Marfil; Romina Cabrera-Rodríguez; Raquel Ortiz; Víctor Urrea; Carla Rovirosa; Judith Estévez-Herrera; Isabel Olivares; Concepción Casado; Cecilio Lopez-Galindez; Julià Blanco; Agustín Valenzuela-Fernández
Journal:  Front Microbiol       Date:  2022-03-24       Impact factor: 5.640

6.  Parallel analysis of transcription, integration, and sequence of single HIV-1 proviruses.

Authors:  Kevin B Einkauf; Matthew R Osborn; Ce Gao; Weiwei Sun; Xiaoming Sun; Xiaodong Lian; Elizabeth M Parsons; Gregory T Gladkov; Kyra W Seiger; Jane E Blackmer; Chenyang Jiang; Steven A Yukl; Eric S Rosenberg; Xu G Yu; Mathias Lichterfeld
Journal:  Cell       Date:  2022-01-12       Impact factor: 41.582

7.  Early treatment regimens achieve sustained virologic remission in infant macaques infected with SIV at birth.

Authors:  Xiaolei Wang; Eunice Vincent; Summer Siddiqui; Katherine Turnbull; Hong Lu; Robert Blair; Xueling Wu; Meagan Watkins; Widade Ziani; Jiasheng Shao; Lara A Doyle-Meyers; Kasi E Russell-Lodrigue; Rudolf P Bohm; Ronald S Veazey; Huanbin Xu
Journal:  Nat Commun       Date:  2022-08-16       Impact factor: 17.694

8.  Genotypic and Phenotypic Diversity of the Replication-Competent HIV Reservoir in Treated Patients.

Authors:  Alexandre Nicolas; Julie Migraine; Jacques Dutrieux; Maud Salmona; Alexandra Tauzin; Atsuko Hachiya; Jérôme Estaquier; Jean-Michel Molina; François Clavel; Allan J Hance; Fabrizio Mammano
Journal:  Microbiol Spectr       Date:  2022-06-30

9.  Selective miRNA inhibition in CD8+ cytotoxic T lymphocytes enhances HIV-1 specific cytotoxic responses.

Authors:  Nadia Madrid-Elena; Sergio Serrano-Villar; Carolina Gutiérrez; Beatriz Sastre; Matías Morín; Laura Luna; Laura Martín; Javier Santoyo-López; María Rosa López-Huertas; Elena Moreno; María Laura García-Bermejo; Miguel Ángel Moreno-Pelayo; Santiago Moreno
Journal:  Front Immunol       Date:  2022-09-26       Impact factor: 8.786

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.